期刊文献+

雷贝拉唑与兰索拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡疗效比较 被引量:2

Efficacy of Rabeprazole-based Versus Therapy on Helicobacter Pylori Positive Peptic Ulcer with Lansoprazole-based Triple
下载PDF
导出
摘要 目的:比较雷贝拉唑三联疗法与兰索拉唑三联疗法治疗幽门螺杆菌阳性消化性溃疡的疗效。方法:将幽门螺杆菌阳性的消化性溃疡83例分为两组:治疗组(雷贝拉唑三联疗法组)41例,以雷贝拉唑10mg,阿莫西林1000mg及甲硝唑400mg每日2次口服,治疗1周后单独服用雷贝拉唑10mg,连服7d;对照组(兰索拉唑三联疗法组)42例:以兰索拉唑30mg,阿莫西林1000mg及甲硝唑400mg,每日2次口服,治疗1周后单独服用兰索拉唑30mg,连服7d。治疗期间每周门诊随诊,记录临床症状改善情况,用药结束1个月后复查胃镜并检测幽门螺杆菌结果。结果:治疗组和对照组1d的临床症状缓解率分别为80%、60%,差异有统计学意义(P<0.05);1周后症状缓解率均为98%。治疗组和对照组的溃疡愈合率分别为93%和76%,差异有统计学意义(P<0.05);治疗组和对照组的总有效率分别为98%和96%,差异无统计学意义(P>0.05)。治疗组和对照组的幽门螺杆菌根除率分别85%和81%,差异无统计学意义(P>0.05)。结论:两组方案均能有效治疗消化性溃疡和缓解临床症状,并能有效地根除幽门螺杆菌。但雷贝拉唑三联疗法在改善临床症状和促进溃疡愈合方面优于兰索拉唑三联疗法。 Objective: To compare the efficacy of mrabeprazole-based and lansoprazole-based triple therapy in the treatment of Helieobacter pylori (H pylori) -positive peptic ulcer. Methods: Eighty-three patients with H pylori positive peptic ulcers were randomized into two groups: the 1st group treated with rabeprazole 10 mg bid (rabeprazole-group n= 41 ) and the 2nd group treated with lansoprazole 20 rag bid (lansoprazole-group n=42) for 1 week, all patients were given amoxicillin lg bid and metronidazole 400mg for one week after. Clinical symptoms were observed and recorded weekly. One month after treatment, the eradication rate of H priori and the healing rate of peptic ulcer were evaluated according to result of repeated endoscope. Results: The relief rate for clinical symptoms in rabeprazole-group and lansoprazole- group was 80% and 60% respectively at one day finishing regimen (P 〈 0.05). The relief rate for clinical symptoms in both groups was 98% and 98% respectively at one week finishing regimen (P 〉 0.05), the ulcer healing rate in both groups was 93% and 76% (P 〈 0.05), the global effective rate in both groups was 98%and 96% respectively (P 〉 0.05). And the H pylori eradication rate in both groups was 85% and 81% respectively (P 〉 0.05). Conclusion: Both regimens are effective for curing peptic ulcer, relieving symptoms, and for eradicating H pylor. Rabeprazole-based triple therapy is superior to lansoprazole-based triple therapy in improving symptoms and curing ulcers.
出处 《岭南急诊医学杂志》 2006年第1期34-36,共3页 Lingnan Journal of Emergency Medicine
关键词 雷贝拉唑 三联疗法 消化性溃疡 兰索拉唑 幽门螺杆菌 Rabeprazole triple therapy peptic ulcer Lansoprazole Helicobacter pylori
  • 相关文献

参考文献3

二级参考文献29

  • 1柯美云,蓝宇,王智风,邢进宏.功能性消化不良昼夜胃内pH变化[J].临床消化病杂志,1995,7(3):97-100. 被引量:13
  • 2李瑜元,吴惠生,聂玉强,黎庆宁.低剂量三联疗法治疗十二指肠溃疡和根除幽门螺杆菌疗效观察[J].新医学,1996,27(5):245-246. 被引量:14
  • 3李益农.H2受体拮抗剂治疗.消化性溃疡[M].北京:人民卫生出版社,1998.479.
  • 4周殿元.幽门螺杆菌感染的药物治疗.胃肠病临床药理学[M].北京:科学出版社,1998.493.
  • 5陈灏珠.实用内科学(第10版)[M].北京:人民卫生出版社,1997.1410-1413.
  • 6Martin JM Buckley 等.幽门螺杆菌感染的治疗[J].中华消化杂志,1997,19:46-47.
  • 7Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors. Am J Gastroenterol, 1998 ; 93 (5) : 763 - 767.
  • 8Bianco A, Cagossi M, Piraccini R, et al. The nightly spontaneous alkalinization of the stomach. Riv Eur Sei Med Farmaeol,1993 ; 15(1) : 17 -27.
  • 9Robinson M. New-generation proton pump inhibitors; overcoming the limitations of early-generation agents. Eur J Gastroenterol Hepatol,2001 ; 13(suppl. 1) :S43-S47.
  • 10Tytgat GNJ. Shortcomings of the first-generation proton pump inhibitors. Eur J Gastroenterol Hepatoh 2001 ; 13 ( suppl. 1) : S29- S33.

共引文献168

同被引文献28

引证文献2

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部